重要内容提示： 证券代码：688068 证券简称：热景生物 公告编号：2024-045 北京热景生物技术股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 5 月 21 日 （二） 股东大会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业 基地庆丰西路 55 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 45 | | --- | --- | | 普通股股东人数 | 45 | | 2、出席会议的股东所持有的表决权数量 | 37,199,825 | | 普通股股东所持有表决权数量 | 37,199,825 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 42.8963 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 4 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2023 年年度股东大会的法律意见书 康达股会字【2024】第1814号 致：北京热景生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称"《规则》"）、《北 京热景生物技术股份有限公司章程》（以下简称"《公司章程》"）及北京热景生物技术 股份有限公司（以下简称"公司"）与北京市康达律师事务所（以下简 ...

北京市东卫律师事务所 关于北京热景生物技术股份有限公司 2024年员工持股计划之 法律意见书 2024年员工持股计划之 法律意见书 东卫法意第 178 号 北京市东卫津师事务所 BEIJING DONGWEI LAW FIRM 北京市东城区朝阳门北大街8号富华大厦D座3层 电话:010-65542826 邮编:100027 北京市东卫律师事务所 关于北京热景生物技术股份有限公司 2024年员工持股计划之法律意见书 北京市东卫律师事务所 关于北京热景生物技术股份有限公司 对于本法律意见至关重要而又无法得到独立证据支持的事实,本所依赖于有 关政府部门、公司或其他有关单位出具的证明文件出具本法律意见。本所律师仅 北京市东卫律师事务所 关于北京热景生物技术股份有限公司 2024年员工持股计划之法律意见书 本法律意见仅供公司为实施本员工持股计划之目的使用,不得用作任何其他 目的。本所同意公司在实施本员工持股计划所制作的相关文件中引用本法律意见 的相关内容,但公司作上述引用时,不得因引用而导致歧义或曲解,本所有权对 相关文件的相应内容再次审阅并确认。 就本法律意见出具之目以前已经发生的事实进行法律审查,发表法律意见,并不 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-044 北京热景生物技术股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 29 日(星期三) 至 06 月 04 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hotgen@hotgen.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京热景生物技术股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发布公司 2023 年年度报告、2024 年第一季度报告，为便于广大投资者更全面 深入地了解公司 2023 年度及 2024 年第一季度经营成果、财务状况，公司计划于 2024 年 06 月 05 日下午 14:00-15:00 举行 2023 年度 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-042 北京热景生物技术股份有限公司 关于股份回购实施结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/8 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 3 个月 | | 预计回购金额 | 元~150,000,000 元 75,000,000 | | 回购价格上限 | 53.00 元/股 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | √为维护公司价值及股东权益 | | 实际回购股数 | 股 2,893,010 | | 实际回购股数占总股本比例 | 3.13% | | 实际回购金额 | 元 92,016,460.62 | | 实际回购价格区间 | 27.28 元/股~33.79 元/股 | 一、 回购审批情况和回购方案内容 公司于 2024 年 2 月 7 日召开了第三届董事会第十七次会议，审议通过了《关 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-041 北京热景生物技术股份有限公司 2020 年限制性股票激励计划首次授予部分第二个归属 期及预留授予部分第一个归属期归属结果暨股份上市 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 205,926 股。 本次股票上市流通总数为 205,926 股。 本次股票上市流通日期为 2024 年 5 月 10 日。 同日，公司召开第二届监事会第十一次会议，审议通过了《关于审议公司<2020 年限制性股票激励计划（草案）>及其摘要的议案》《关于审议公司<2020 年限制 性股票激励计划实施考核管理办法>的议案》以及《关于核实公司<2020 年限制性 股票激励计划激励对象名单>的议案》，公司监事会对本激励计划的相关事项进行 核实并出具了相关核查意见。 2、2020 年 5 月 22 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《北京热景生物技术股份有限公司关于 ...

Financial Performance - The company's operating revenue for 2023 was ¥541,251,205.97, a decrease of 84.78% compared to ¥3,556,551,569.15 in 2022 [21]. - The net profit attributable to shareholders for 2023 was ¥27,382,940.50, down 97.10% from ¥944,736,633.48 in the previous year [21]. - The cash flow from operating activities for 2023 was -¥51,949,238.20, a decline of 105.31% compared to ¥978,753,167.93 in 2022 [21]. - The basic earnings per share for 2023 was ¥0.31, a decrease of 97.00% from ¥10.33 in 2022 [22]. - The diluted earnings per share for 2023 was also ¥0.31, reflecting a decrease of 96.98% from ¥10.28 in 2022 [22]. - The company reported a net profit excluding non-recurring gains and losses of -¥59,329,923.26 for 2023, compared to ¥942,414,646.53 in 2022, marking a decline of 106.30% [21]. - The total assets at the end of 2023 were ¥3,560,592,952.10, down 8.69% from ¥3,899,271,839.82 at the end of 2022 [21]. - The net assets attributable to shareholders at the end of 2023 were ¥3,359,976,486.12, a slight increase of 0.74% from ¥3,335,223,635.33 in 2022 [21]. - The weighted average return on net assets for 2023 was 0.82%, a decrease of 29.59 percentage points from 30.41% in 2022 [22]. - The company achieved a net profit attributable to the parent company of 27.38 million yuan in 2023, a decrease of 97.10% compared to the previous year, primarily due to a decline in unconventional business and high R&D expenditures [143]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 24.29% in 2023, up from 5.37% in 2022, representing an increase of 18.92 percentage points [22]. - The company invested CNY 131.45 million in R&D in 2023, accounting for 24.29% of its revenue, an increase of 18.91 percentage points compared to the previous year [46]. - The company maintained a high level of R&D investment despite a decrease in overall revenue, with R&D expenses down 31.23% year-on-year [24]. - The company has established the "X-Gen AI Drug Discovery and Design Research Center" to accelerate new drug development using AI technology, enhancing its antibody and nucleic acid drug research pipeline [40]. - The company is focusing on the development of therapeutic antibody drugs and nucleic acid drugs in the biopharmaceutical innovation sector [85]. - The company has launched several new diagnostic products, including a cardiac marker BNP assay kit and a tumor marker VEGF assay kit, and initiated clinical trials for its innovative exosome cancer screening technology [47]. - The company has established multiple advanced technology platforms, including phage display technology and glycan capture technology, enhancing its core competitiveness in the field of in vitro diagnostics [89]. Market and Strategic Initiatives - The company is actively expanding its strategic layout in the fields of antibody drugs, live bacteria drugs, and nucleic acid drugs [35]. - The company is exploring innovative technologies in the biopharmaceutical field, including antibody drugs and nucleic acid drugs [108]. - The company is committed to ongoing R&D to meet diverse clinical testing needs, demonstrating organizational agility in responding to market changes [141]. - The company is focusing on expanding its existing business scale in the in vitro diagnostics sector, adhering to the principle of "innovative diagnosis, value testing" [198]. - The company aims to expand its market share in clinical medical testing and early detection of liver cancer, focusing on technology research and development [199]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the industry [192]. - The company has established a comprehensive strategic layout from high-precision UPT series platforms to large-scale fully automated chemiluminescence platforms, targeting both grassroots and high-end medical markets [63]. Corporate Governance and Compliance - The audit report issued by the accounting firm was a standard unqualified opinion, ensuring the accuracy of the financial statements [5]. - The board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report [4]. - The company has not violated any decision-making procedures regarding external guarantees [7]. - The company has established a comprehensive quality control system that includes various departments to ensure product quality throughout the entire lifecycle [138]. - The company’s internal governance system has been continuously improved to enhance operational efficiency and compliance with market regulations [53]. Social Responsibility and Community Engagement - The company donated a total of 2 million yuan to various charitable causes, including disaster relief and health initiatives, demonstrating its commitment to social responsibility [59]. - The company has received over 60 honors, including "Beijing Enterprise Technology Center" and "Beijing Knowledge Property Operation Pilot Unit," reflecting its strong reputation in the industry [56]. Risks and Challenges - The company faces risks related to new product development, including potential delays and failures due to technical route deviations and market positioning issues [144]. - The company acknowledges the risk of core technical personnel turnover, which could hinder ongoing projects and product development [144]. - The IVD industry is experiencing intensified competition, with both domestic and international players vying for market share, necessitating continuous innovation and quality improvement from the company [147]. - The company faces risks related to product pricing declines due to government policies and market competition [148]. - The company must adapt to rapid technological advancements in the in vitro diagnostics industry to mitigate risks associated with technological upgrades [150].

Financial Performance - The company's operating revenue for Q1 2024 was ¥116,124,860.44, representing a decrease of 42.78% compared to the same period last year[5] - The net profit attributable to shareholders was ¥5,054,819.80, down 91.42% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥33,946,415.33, a decline of 167.83%[5] - Basic earnings per share were ¥0.06, down 90.91% year-on-year[6] - Operating profit for Q1 2024 was ¥5,445,201.51, down from ¥68,617,202.23 in Q1 2023, reflecting a significant decline[18] - The company reported a total comprehensive income of ¥3,530,809.12 for Q1 2024, significantly lower than ¥56,095,829.44 in Q1 2023[19] - The company experienced a significant reduction in research and development expenses, which were ¥22,667,361.22 in Q1 2024 compared to ¥33,864,932.96 in Q1 2023, indicating a strategic shift[17] Cash Flow and Assets - The net cash flow from operating activities was -¥14,007,005.61, reflecting a decrease of 94.23% compared to the previous year[5] - Cash flow from operating activities for Q1 2024 was negative at -¥14,007,005.61, an improvement from -¥242,784,347.60 in Q1 2023[22] - Cash inflow from investment activities for Q1 2024 was ¥190,685,063.58, compared to ¥607,831,021.95 in Q1 2023[22] - Cash outflow from investment activities for Q1 2024 was ¥127,419,498.65, down from ¥561,508,312.58 in Q1 2023[22] - The net cash flow from financing activities was -$86,960,469.79, compared to -$6,483,618.22 in the previous year, indicating a significant increase in cash outflow[23] - The net increase in cash and cash equivalents for the quarter was -$37,780,115.99, compared to -$204,230,354.41 in the same quarter last year, showing an improvement in cash management[23] - The ending balance of cash and cash equivalents was $234,606,511.59, down from $318,984,364.49 year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,485,480,510.90, a decrease of 2.11% from the end of the previous year[6] - As of March 31, 2024, total assets amounted to CNY 3,485,480,510.90, a decrease from CNY 3,560,592,952.10 as of December 31, 2023, reflecting a decline of approximately 2.1%[14] - Current assets totaled CNY 1,090,874,769.22, an increase from CNY 828,236,988.59, representing a growth of approximately 31.7%[15] - Total liabilities amounted to CNY 205,340,125.40, a slight increase from CNY 202,561,988.73, reflecting a growth of approximately 1.4%[16] - The company's equity remained stable with total equity at CNY 3,280,140,385.50 as of March 31, 2024[16] Market and Product Development - The company experienced a significant reduction in unconventional COVID-19 business, which accounted for approximately 50% of revenue in the previous year[8] - The company reported a rapid growth of over 27% in its core hepatitis and liver cancer diagnostic reagents[8] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[13] Accounting and Reporting Changes - The company has adopted new accounting standards starting in 2024, which may impact financial reporting[23]

近日，公司已完成工商变更登记手续，并取得了由北京市大兴区市场监督管 理局换发的《营业执照》，公司住所由"北京市大兴区中关村科技园区大兴生物 医药产业基地天富街9号9幢"变更为"北京市大兴区中关村科技园区大兴生物医 药产业基地庆丰西路55号院7号楼1-5层"。公司根据经营发展需要，已搬迁至新 办公地址，公司主要办公地址变更为"北京市大兴区中关村科技园区大兴生物医 药产业基地庆丰西路55号院7号楼1-5层"。除上述变更事项外，公司其他联系方 式均保持不变。 证券代码：688068 证券简称：热景生物 公告编号：2024-028 北京热景生物技术股份有限公司 关于完成工商变更登记及变更办公地址的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第三届董事会第十五次会议和 2024 年 2 月 2 日召开的 2024 年第一次临 时股东大会审议通过了《关于修订<公司章程>的议案》，具体内容详见公司在上 海证券交易所网站（www.sse.co ...

北京热景生物技术股份有限公司 关于以集中竞价交易方式回购公司股份比例 达到总股本 3%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688068 证券简称：热景生物 公告编号：2024-027 公司于 2024 年 2 月 7 日召开了第三届董事会第十七次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，为维护公司价值及股东权益， 同意公司以自有资金通过集中竞价交易方式回购公司 A 股股份，回购价格不超过 人民币 53.00 元/股（含），回购资金总额不低于人民币 7,500 万元（含），不超过 人民币 15,000 万元（含），回购期限自董事会审议通过本次回购方案之日起 3 个 月内。 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《北京热 景生物技术股份有限公司关于以集中竞价交易方式回购公司股份方案的公告》（公 告编号：2024-012）、《北京热景生物技术股份有限公司关于以集中竞价交易方式回 购股份的回购报告书》（公告编号：2024-014）。 二 ...